Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05115435 |
Other study ID # |
RDNLP |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
March 1, 2021 |
Est. completion date |
November 1, 2021 |
Study information
Verified date |
November 2021 |
Source |
Inonu University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The study was conducted experimentally to evaluate the effect of neurolinguistic programming
on COVID-19 fear in kidney transplant patients.
Description:
The study was conducted experimentally (prospective randomized single-blind clinical trial
model) to evaluate the effect of neurolinguistic programming (NLP) on fear of Covid-19 in
kidney transplant patients.
The study was carried out between June 2021 and October 2021. Personal Information Form and
Fear of COVID-19 Scale (FCV-19S) were used to collect data. The data obtained from the
research were evaluated with SPSS 25.
According to the calculation made using G*power 3.1 software, the sample size was determined
as 74 (each group 37) with an effect size of 0.80, a margin of error of 0co.05, a confidence
level of 0.95, and a population representation of 0.95. Simple random sampling method, one of
the probability sampling methods, was used to determine the participants. Single-group
columns between 1 and 300 were created using the Random Integer Generator method, which
located in the Numbers sub-heading of the random.org website for the participants who met the
sample selection criteria. Participants were randomly assigned to numbers 1 and 2,
considering the numbers 1 and 2 in the column. The number of the experimental or control
group was determined by drawing lots at the beginning of the research